[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adpkd-autosomal-dominant-polycystic-kidney-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adpkd-autosomal-dominant-polycystic-kidney-disease":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,53,82,107,127,146,168,198],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100614686","phase-2-bempedoic-acid-therapy-for-polycystic-kidney-disease-100614686",false,"NCT07282821","Bempedoic Acid Therapy for Polycystic Kidney Disease","Bempedoic Acid Therapy for Polycystic Kidney Disease (BEAT-PKD) Randomized Clinical Trial","BEAT-PKD","Inclusion Criteria:\n\n* ADPKD patients as defined by Pei-Ravine criteria\n* Age 18-60 years\n* Mayo Imaging Classifications (MIC) 1C-1E or MIC 1B with defined eGFR decline \\>3 ml\u002Fmin\u002F1.73m2\u002Fyr (estimated from serum creatinine using the CKD-Epi equation)\n* Estimated glomerular filtration rate (eGFR) ≥35 ml\u002Fmin\u002F1.73m2 by CKD-Epi equation utilizing creatinine\n* Fluent English-speaking\n* Able to provide informed consent\n* Patients with and without current tolvaptan use (prescribed by primary nephrologist) at a stable dose for ≥3 months\n\nExclusion Criteria:\n\n* Estimated GFR\\\u003C35 ml\u002Fmin\u002F1.73m2 (estimated from serum creatinine using the CKD-Epi equation)\n* Proteinuria \\>500 mg\u002Fday\n* Current bempedoic acid (BA) use or history of hypersensitivity to BA\n* Diabetes (currently diagnosed, or fasting glucose \\>125 mg\u002FdL)\n* Serum uric acid \\>10 mg\u002FdL or 1 or more acute gout flare within the prior year\n* Known active hepatitis or abnormal baseline liver function tests (LFTs) which is defined for patients who are not taking concomitant tolvaptan as ALT, AST or direct bilirubin \\>1.5X ULN (upper limits of normal), or, for patients taking tolvaptan, as an ALT, AST, or direct bilirubin \\>ULN\n* Known unstable cerebral aneurysm\n* Active coronary artery disease, defined as presence of stable or unstable angina\n* Systemic disease (other than hypertension) likely to contribute to kidney disease (e.g., lupus)\n* Current use of simvastatin \\>20 mg or pravastatin \\>40 mg daily.\n* Pregnancy or lactation\n* Hemoglobin \\\u003C10 g\u002FdL\n* Implanted ferromagnetic objects\n* Use of an investigational product within prior 30 days or 5 half-lives, whichever is longer","ALL","18 Years","60 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Autosomal dominant polycystic kidney disease (ADPKD), the most commonly inherited kidney disease, is characterized by the development of cysts in the kidney that impair function. Of those affected, half will progress to end-stage kidney disease by age 60, requiring dialysis or kidney transplant. To date, no effective and safe therapies exist for this deadly disease. Tolvaptan (Tol), the only FDA-approved drug for treatment of ADPKD, has some benefit in slowing kidney disease progression, but Tol causes frequent urination and thirst and also injures the liver in a small number of patients. The investigators' goal, therefore, is to develop new strategies to treat ADPKD that are safe and tolerable.\n\nThe development of cysts in ADPKD patients results from two main cellular processes. The first is cell growth with an increase in the number of kidney cells that make up the outer surface of the cyst. The second is an increase in fluid secretion into the cysts that develop. The investigators have shown that an enzyme, AMP-activated protein kinase (AMPK), when activated can inhibit both of those processes. Moreover, genetic mutations that cause ADPKD may alter the energy metabolism of the cell, which in turn inhibits AMPK activity. Bempedoic acid (BA), a medication that is FDA-approved for the treatment of individuals with high cholesterol and has a good safety record, activates AMPK. In addition to activating AMPK, BA inhibits a second enzyme called ATP-citrate lyase (ACLY), which is involved in cholesterol synthesis. ACLY has received growing attention as a novel target for cancer treatment. ACLY inhibition blocks increases of cell numbers by inhibiting the lipid synthesis that is required for creation of new cell membranes. This study will test whether targeting these pathways through treatment with BA will help reverse dysfunctional metabolism in individuals with ADPKD and slow disease progression.\n\nThe investigators will test this using a phase 2 clinical trial in which 120 individuals with rapidly progressive ADPKD and an estimated glomerular filtration rate of 35 or greater will be treated with either BA or placebo (inactive look-alike pill) for two years. Participants on or off a stable dose of Tol will be included in the study. Participants will be recruited from the U. of Vermont, U. of Maryland, and Tufts University, which have active PKD clinics and are recognized by the PKD Foundation as Centers of Excellence. Through follow-up visits and lab work, the investigators will assess the safety and tolerability of BA in the participants as the primary outcomes. The secondary goals are to assess preliminary efficacy and effects of BA on quality of life in study participants. The growth of cysts results in increased volume or size of the kidneys and liver. Total and cyst volumes of the kidney and liver and visceral abdominal fat content via magnetic resonance imaging (MRI) will be measured to gauge the effectiveness of this drug. The investigators also predict that proteins and small molecules involved in regulating cell energy metabolism, inflammation, and injury, as well as proteins directly involved in AMPK and ACLY function, will be altered in ADPKD patients. Levels of these proteins and small molecules may then subsequently change with BA therapy. Exploratory, mechanistic goals of this study are to identify prognostic and predictive urinary biomarkers in study participants. Successful completion of this study would have a significant impact on individuals with ADPKD by laying the groundwork for a new treatment strategy as well as by providing a new way to help guide treatment decisions.\n\nIn summary, the goals of this phase 2 randomized, double-blind, placebo-controlled clinical trial are to test the safety, tolerability and preliminary efficacy of the drug bempedoic acid, FDA-approved to lower cholesterol, when used in ADPKD patients.",[28],"ADPKD (Autosomal Dominant Polycystic Kidney Disease)",[30,31,32,33,34,35,36,37,38,39],"ADPKD","bempedoic acid","AMPK","ACLY","height-adjusted total kidney volume","biomarkers","MRI","urine","metabolism","tolvaptan","NOT_YET_RECRUITING","2026-04-29",{"date":43,"type":44},"2026-05-01","ACTUAL",{"date":46,"type":22},"2026-07-27",{"date":48,"type":22},"2030-02-28",{"name":50,"class":51},"Kenneth Hallows","OTHER",3,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":61,"targetDuration":63,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":67,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100247281","the-german-adpkd-tolvaptan-treatment-registry-100247281","NCT02497521","The German ADPKD Tolvaptan Treatment Registry","The German ADPKD Tolvaptan Treatment Registry is a Prospective, Observational, Multicentric Study of Patients Suffering From ADPKD That Are Considered for Tolvaptan Treatment.","AD(H)PKD","Inclusion Criteria:\n\n* Age \\> 18 years\n* ADPKD proven by positive family history and evidence of renal cysts or diagnosed by treating physician\n* Presentation at our center for tolvaptan treatment indication, or tolvaptan treatment planned, or tolvaptan already started\n\nExclusion Criteria:\n\n* Patients not capable of giving informed consent\n* End stage renal disease requiring renal replacement therapy\n* Patients receiving tolvaptan as \"off-label use\"",{"count":62,"type":22},2000,"10 Years","OBSERVATIONAL","The German ADPKD Tolvaptan Treatment Registry is a prospective, observational, multicentric study of patients suffering from ADPKD that are considered for tolvaptan treatment. All ADPKD patients that are evaluated for treatment indication, or that are planned to be treated with tolvaptan, or that are already treated with tolvaptan are eligible. This registry is designed to provide \"real-world\" data on treatment management of patients with ADPKD.",[28],[68,69,30,70,71],"polycystic kidney disease","autosomal dominant polycystic kidney disease","Tolvaptan","Jinarc","RECRUITING",{"date":74,"type":44},"2026-04-30",{"date":76,"type":44},"2015-11",{"date":78,"type":22},"2027-12",{"name":80,"class":51},"University of Cologne",12,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":17,"minAge":18,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":4},"100636419","phase-1-drug-drug-interactions-of-jmkx003142-in-healthy-participants-100636419","NCT07565441","Drug-Drug Interactions of JMKX003142 in Healthy Participants","A Single-center, Non-randomized, Open-label, Self-controlled, Phase I Clinical Study to Evaluate Drug-Drug Interactions (DDI) of JMKX003142 Tablets in Chinese Healthy Participants.","Inclusion Criteria:\n\n1. Participants are able to return to the study center for follow-up as required by the protocol and are willing to comply with study policies, procedures, and restrictions; capable of effective communication with the investigator and completing study-related materials; able to understand the contents of the Informed Consent Form (ICF) and sign the written ICF prior to any study procedures.\n2. Healthy Chinese male or female subjects, as determined by medical history and physical examination. At the time of signing the Informed Consent Form (ICF), aged 18-45 years (inclusive) ; body weight ≥ 50 kg for males or ≥ 45 kg for females; and Body Mass Index (BMI) within the range of 19.0-26.0 kg\u002Fm² (inclusive).\n3. Participants were considered healthy by the Investigator based on medical history, baseline physical examination, clinical laboratory assessments, and 12-lead ECG, with all results judged as normal or not clinically significant.\n4. Participants of childbearing potential who agree to use effective contraception and have no plans for conception, cryopreservation, or donation of gametes from ICF signature through 3 months after the last dose.\n\nExclusion Criteria:\n\n1. Known or suspected hypersensitivity to JMKX003142 (active ingredient or excipients), or a history of hypersensitivity to more than two drugs, foods, or other substances.\n2. History or presence of clinically significant diseases in any of the following systems (including but not limited to): cardiovascular, respiratory, gastrointestinal, hematologic, genitourinary, endocrine\u002Fmetabolic, nervous, psychiatric, musculoskeletal, dermatologic, lymphatic, immune, or sensory organs; or current active local or systemic infection.\n3. Any condition increasing the risk of bleeding, such as acute gastritis, active ulcer with hemorrhage, clinically significant thrombocytopenia or anemia, active pathological bleeding, or a history of intracranial hemorrhage.\n4. Vital signs meet any of the following criteria at screening: systolic blood pressure ≥ 140 mmHg or \\\u003C 90 mmHg; diastolic blood pressure ≥ 90 mmHg or \\\u003C 50 mmHg; pulse rate \\> 100 bpm or \\\u003C 50 bpm; or tympanic temperature ≥ 37.5°C or \\\u003C 35°C.\n5. Subjects with a history of QTc interval prolongation or a family history of Long QT Syndrome; or those with clinically significant abnormal ECG findings as determined by the Investigator during screening; or a QTcF ≥ 450 ms; or a QRS interval \\> 120 ms.\n6. Positive for Hepatitis B surface antigen (HBsAg), Hepatitis C virus (HCV) antibody, Human Immunodeficiency Virus (HIV) antibody, or syphilis serology.\n7. Treatment with therapeutic biological products within 3 months (or 5 half-lives, whichever is longer) prior to dosing, or other prescription\u002Fnon-prescription medications (including vaccines, Traditional Chinese Medicine \\[TCM\\], dietary supplements, and health products) within 1 month (or 5 half-lives, whichever is longer).\n8. Use of any investigational drug within 3 months prior to screening, or current participation in another clinical trial.\n9. Major surgery (e.g., requiring general or epidural anesthesia) within 3 months prior to screening, or planned surgical intervention during the study.\n10. History of hemophobia, belonephobia, or difficult venous access.\n11. Blood donation or blood loss of ≥400 mL within 3 months prior to screening.\n12. History of drug dependence\u002Fabuse or illicit drug use, or a positive drug screening result.\n13. Smoking ≥5 cigarettes per day within 3 months prior to screening, or inability to commit to abstaining from tobacco products during the study, or a positive nicotine screening result.\n14. History of heavy alcohol consumption (\\>14 units per week; 1 unit ≈ 10 mL alcohol, equivalent to approx. 285 mL beer \\[3.5%\\], 25 mL spirits \\[40%\\], or 100 mL wine \\[10%\\]), inability to abstain from alcohol after screening, or a positive alcohol breath test.\n15. Daily consumption of excessive tea, coffee, or caffeine-containing beverages (more than 8 cups per day; 1 cup = 250 mL) within 14 days prior to screening.\n16. Ingestion of grapefruit or grapefruit-related citrus fruits (e.g., Seville oranges, pomelos) or fruit products within 3 days prior to dosing.\n17. Special dietary requirements, or inability to comply with a standardized diet (e.g., standard meals) and dietary restrictions.\n18. Pregnancy or lactation, positive pregnancy test in females, unprotected sexual intercourse with a partner within 14 days prior to screening, use of oral contraceptives within 30 days prior to screening, or use of long-acting injectable or implanted estrogens\u002Fprogestogens within 6 months prior to screening.\n19. Requirement to drive long distances, work at heights, or operate complex machinery during the study.\n20. Other conditions that, in the investigator's opinion, would make the subject unsuitable for participation in this study.",true,"45 Years",{"count":92,"type":22},112,[94],"PHASE1","This is a single-center, non-randomized, open-label, self-controlled, Phase I clinical trial to evaluate the drug-drug interactions (DDI) of JMKX003142 tablets in healthy adult participants.\n\nThe study consists of five cohorts (Cohorts 1, 2, 3, 4, and 5). A total of 24 participants are planned enrollment in each of Cohorts 1, 2, 3, and 5, while 16 participants are planned for Cohort 4.",[28],"2026-04-27",{"date":99,"type":44},"2026-05-04",{"date":101,"type":22},"2026-05-11",{"date":103,"type":22},"2027-02-28",{"name":105,"class":106},"Jemincare","INDUSTRY",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":89,"sex":17,"minAge":18,"maxAge":90,"enrollmentInfo":114,"targetDuration":4,"studyType":23,"phases":116,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":4},"100629094","phase-1-a-study-to-investigate-the-effects-of-jmkx003142-on-qtc-interval-in-healthy-adults-100629094","NCT07470177","A Study to Investigate the Effects of JMKX003142 on QTc Interval in Healthy Adults","A Single-center, Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Effect of a Single-dose of JMKX003142 on QTc Intervals in Healthy Participants","Inclusion Criteria:\n\n1. Participants must be able to return to the study center for follow-up visits as required by the protocol and be willing to comply with study policies, procedures, and constraints. They must be able to communicate effectively with the investigator, complete study-related materials, and understand the contents of the Informed Consent Form (ICF). A written ICF must be signed before any study-specific procedures are performed.\n2. Healthy Chinese males or females based on medical history and physical examination. At the time of signing the informed consent form (ICF), participants must be aged 18 to 45 years (inclusive), with a body weight ≥ 50 kg and a body mass index (BMI) between 19.0 and 28.0 $kg\u002Fm\\^2 (inclusive).\n3. Participants' health status will be determined by the investigator based on medical history, physical examination, clinical laboratory tests, and 12-lead electrocardiogram (ECG). All test results must be confirmed by the investigator as either normal or abnormal without clinical significance (NCS).\n4. Participants of childbearing potential must have no plans to conceive, freeze, or donate sperm\u002Feggs from the time of signing the informed consent form (ICF) until 3 months after the last dose, and must agree to use highly effective contraception methods.\n\nExclusion Criteria:\n\n1. History or presence of clinically significant diseases, including but not limited to: cardiovascular, respiratory, gastrointestinal, hematological, genitourinary, endocrine and metabolic, neurological, psychiatric, musculoskeletal, dermatological, lymphatic, or immunological systems, or diseases of the sense organs, as well as current systemic or local acute\u002Fchronic infections.\n2. Participants with any condition that increases the risk of bleeding, such as acute gastritis or active ulcers with bleeding, clinically significant thrombocytopenia or anemia, active pathological bleeding, or a history of intracranial hemorrhage.\n3. Vital signs at screening that meet any of the following criteria: systolic blood pressure (SBP) ≥ 140 mmHg or \\\u003C 90 mmHg; diastolic blood pressure (DBP) ≥ 90 mmHg or \\\u003C 50 mmHg; pulse rate \\> 100 bpm or \\\u003C 50 bpm; or axillary temperature \\> 37.2°C.\n4. History of QTc interval prolongation, or any clinically significant abnormal ECG findings at screening as determined by the investigator, or QTcF ≥ 450 ms, or QRS duration \\> 120 ms, or PR interval ≥ 200 ms.\n5. Clinical laboratory test results at screening showing serum potassium, magnesium, or calcium levels outside the normal range and judged by the investigator to be clinically significant.",{"count":115,"type":22},24,[94],"The primary objective of this study is to assess the effect of a therapeutic and supratherapeutic oral dose of JMKX003142 on the corrected cardiac QT interval relative to a placebo in healthy participants",[28],"2026-03-10",{"date":121,"type":44},"2026-03-13",{"date":123,"type":22},"2026-03-27",{"date":125,"type":22},"2026-06-23",{"name":105,"class":106},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":89,"sex":134,"minAge":18,"maxAge":90,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":4},"100628547","phase-1-mass-balance-and-absolute-bioavailability-study-of-jmkx003142-in-healthy-volunteers-100628547","NCT07463053","Mass Balance and Absolute Bioavailability Study of JMKX003142 In Healthy Volunteers","A Study to Evaluate the Mass Balance and Absolute Bioavailability of [14C]JMKX003142 in Healthy Male Participants","Inclusion Criteria:\n\n1. Chinese healthy males.\n2. The age between 18 and 45 years (extremes included), on the date of signing the informed consent form (ICF).\n3. Body mass index (BMI) range of 19-26.0 kg\u002Fm² (inclusive of boundary values), with body weight not less than 55.0 kg.\n\nExclusion Criteria:\n\n1. Abnormal findings with clinical significance on comprehensive physical examination, vital signs, digital rectal examination, laboratory tests (complete blood count, blood biochemistry, coagulation function, urinalysis, fecal routine with occult blood, thyroid function), ophthalmological examination, 12-lead electrocardiogram, chest X-ray (posteroanterior view), and abdominal ultrasound (liver, gallbladder, pancreas, spleen, kidneys).\n2. White blood cell count and\u002For hemoglobin below the lower limit of the normal range in complete blood count.\n3. Resting corrected QT interval (QTcF) \\>450 ms (corrected by Fridericia's formula, QTcF = QT\u002FRR\\^1\u002F3).\n4. Hepatitis B surface antigen or E antigen positive, anti-HCV IgG positive, syphilis treponemal antibody positive, and HIV antigen\u002Fantibody combination test positive.\n5. Subjects with gastrointestinal diseases causing clinically significant symptoms such as nausea, vomiting, diarrhea, or malabsorption syndrome, or those with a history of severe vomiting or diarrhea within one week prior to screening.","MALE",{"count":5,"type":22},[94],"A phase 1 healthy volunteer study to assess the excretion and metabolism as well as the absolute bioavailability of oral JMKX003142. The study will be conducted in two parts: Part 1 to assess the mass balance of JMKX003142 using orally administered radiolabelled JMKX003142; part 2 will assess the absolute bioavailability using JMKX003142 and radiolabelled JMKX003142 as intravenous and oral forms",[28],"2026-03-06",{"date":119,"type":44},{"date":142,"type":22},"2026-03-18",{"date":144,"type":22},"2026-06-11",{"name":105,"class":106},{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":23,"phases":156,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":167},"100577619","phase-2-trial-of-jmkx003142-in-participants-with-rapidly-progressive-autosomal-dominant-polycystic-kidney-disease-adpkd-100577619","NCT06800651","Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)","A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)","Inclusion Criteria:\n\n* Able to understand the procedures of this trial and provide written informed consent voluntarily;\n* Age between 18 to 55 years, male or female;\n* ADPKD diagnostic criteria were met before randomization;\n* Rapidly progressive ADPKD criteria were met.\n\nExclusion Criteria:\n\n* 12 weeks prior to screening, patients had taken tolvaptan or another ADPKD improvers, or patients who were assessed by the investigator to be likely to use diuretic during the trial period;\n* Praticipants who are unable to feel thirst, or have difficulty with fluid\u002Ffood intake;\n* Patients who have previously received decompression surgery for renal cysts; or who received major surgery within 12 weeks before signing the ICF;\n* The investigator think that the praticipant is unable to comply with the requirements of the trial or cannot be evaluated by the trial.","55 Years",{"count":155,"type":22},135,[25],"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMKX003142 in Participants with Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)",[28],"2025-06-30",{"date":161,"type":44},"2025-07-03",{"date":163,"type":44},"2025-03-13",{"date":165,"type":22},"2027-05-30",{"name":105,"class":106},1,{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":23,"phases":179,"briefSummary":181,"conditions":182,"keywords":184,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":197},"100563628","shared-decision-making-for-choosing-autosomal-dominant-polycystic-kidney-disease-treatment-100563628","NCT06618638","Shared Decision Making for Choosing Autosomal DOminant Polycystic Kidney Disease Treatment","Clinical Trial for Shared Decision Making Model for Choosing Pharmacotherapy in ADPKD Patients","SDM-ADOPT","Inclusion Criteria:\n\n* Participants between the age of 18 to 80\n* Participants with a diagnosis with CKD stage 2 or 3\n* Participants with a diagnosis with ADPKD classified as 1C, 1D, or 1E according to Mayo classification\n* Participants with the ability to communicate and use digital devices\n* Participants with no severe visual impairment and cognitive dysfunction\n\nExclusion Criteria:\n\n* Participants who were previously exposured to tolvaptan\n* Participants who are contraindicated to tolvaptan\n* Participants who were judged ineligible by the investigator","80 Years",{"count":178,"type":22},340,[180],"NA","The purpose of this study is to generate clinical evidence and assess the feasibility of a shared decision-making (SDM) model for the selection of Tolvaptan in patients with ADPKD.",[183],"ADPKD (autosomal Dominant Polycystic Kidney Disease)",[185,186,187,70],"Autosomal Dominant Polycystic Kidney Disease","Shared Decision Making","Hybrid Randomized Controlled Trial type 1","2024-11-05",{"date":190,"type":44},"2024-11-07",{"date":192,"type":44},"2024-10-21",{"date":194,"type":22},"2026-09-30",{"name":196,"class":51},"Seoul National University Hospital",9,{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":89,"sex":17,"minAge":18,"maxAge":90,"enrollmentInfo":205,"targetDuration":4,"studyType":23,"phases":207,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":214,"leadSponsor":216,"locationsCount":4},"100566729","phase-1-study-to-evaluate-the-drug-drug-interaction-of-jmkx003142-in-healthy-subjects-100566729","NCT06658964","Study to Evaluate the Drug-drug Interaction of JMKX003142 in Healthy Subjects","A Single-center, Non-randomized, Open-label, Self-controlled Phase 1 Clinical Study to Evaluate Drug-drug Interactions of JMKX003142 Tablets in Healthy Subjects","Inclusion Criteria:\n\n* Fully understand the research content, process, and potential risks of this trial, voluntarily participate in the clinical trial and sign the informed consent,\n* Healthy male and female subjects aged ≥18 years and ≤45 years old, Male weight ≥50kg, female weight ≥45kg, body mass index ≥19 kg\u002Fm2 and ≤28 kg\u002Fm2,\n* The health of the subjects was determined by the investigator based on medical history, physical examination, clinical laboratory examination, and 12-lead electrocardiogram, all of which were determined by the investigator to be normal or not clinically significant.\n\nExclusion Criteria:\n\n* HBV surface antigen, HCV antibody, HIV, or syphilis are positive during screening,\n* At the time of screening, the vital signs are within the following ranges: systolic blood pressure \\\u003C90 mmHg or \\>140 mmHg, diastolic blood pressure \\\u003C50 mmHg or \\>90 mmHg, pulse \\\u003C50 bpm or \\>100 bpm and ear temperature 37.5℃or\\\u003C35℃,\n* More than 5 cigarettes per day during the 3 months prior to screening, Or were unable to quit smoking\u002Fcontaining tobacco products during the trial,\n* Have special requirements for diet and cannot comply with the diet provided and corresponding regulations.",{"count":206,"type":22},48,[94],"To evaluate the effects of oral administration rifampicin or itraconazole capsules on the pharmacokinetics of JMKX003142 in healthy subjects.",[183],"2024-10-23",{"date":212,"type":44},"2024-10-26",{"date":188,"type":22},{"date":215,"type":22},"2025-03-21",{"name":105,"class":106}]